Annel

28/05/2026

False nails, false eyelashes and beauty accessories may look like simple beauty products.

But from a regulatory perspective, they can be much more complex.

A false nail may be an article, not a cosmetic.

A lash adhesive may require CLP review.

A magnetic eyeliner may still be a cosmetic.

A beauty kit may contain several legal product types in one box.

This is where many brands make costly mistakes.

In the final article in our borderline classification series, we explain when nail, lash and beauty accessory products may trigger cosmetic, GPSR, CLP, REACH or mixed compliance routes.

This matters especially for brands importing private label products into the EU or UK.

Supplier declarations are not enough.
Marketplace categories are not enough.
The correct classification should be confirmed before packaging, import and launch.

Read the article in the first comment.

Need help confirming whether your nail, lash or beauty accessory product follows the cosmetic, general product or chemical route?

Annel can help you review the classification and identify the documentation needed before launch.

25/05/2026

A children’s cosmetic product does not need to change formula to create regulatory risk.

Sometimes play value is enough.

A lip gloss kit, bath bomb with a hidden figurine, children’s make-up palette or colour-changing bath product may look like a simple cosmetic product.

But if it encourages play, includes a surprise element, resembles a toy or is presented as a creative activity, the regulatory route may change.

The formula may still be cosmetic.

The presentation may not.

For brands selling children’s products in the EU, UK and USA, this matters before packaging, claims, Amazon listings or social media copy are approved.

In borderline products, “fun” is not just a marketing word.

It can become a classification signal.

19/05/2026

MoCRA has changed how cosmetic brands should prepare for the U.S. market.

For EU brands, CPSR and PIF documentation are valuable, but they are not an automatic passport to the United States.

Before launch, brands should review:

Responsible Person roles
U.S. Agent requirements
facility registration
product listing
safety substantiation
colour additives
adverse event reporting
SPF and OTC drug risks
cosmetic claims

EU compliance is a strong starting point.
But it should be adapted to the FDA system before products are listed, shipped or sold in the U.S.

Read our new article on MoCRA compliance and the key differences between EU and U.S. cosmetic regulation.

Link in the first comment.

13/05/2026

Beauty from within sounds like skincare.

But if the product is swallowed, the regulatory route changes.

Collagen drinks, gummies, capsules and “hair, skin and nails” supplements often use cosmetic language. They promise glow, beauty support or healthier-looking skin.

However, ingestion changes everything.

An ingestible product cannot rely on cosmetic classification simply because the promise is aesthetic. It may need to be assessed under food law, food supplement rules, nutrition and health claims requirements, Novel Food rules or even medicinal product classification.

That means CPSR, PIF and cosmetic notification are not enough if the product is not legally a cosmetic.

Read the article in the first comment.

06/05/2026

EU Omnibus VI Regulation (EU) 2026/909 introduces new restrictions for 12 cosmetic ingredients, including fragrance substances, UV filters, oral care ingredients, hair dye substances and selected metal compounds.

For cosmetic brands, this may mean more than a simple regulatory update.

The key question is:

Are your formulas, raw material files, PIFs and CPSRs still compliant?

The new rules may require:

✓ formula portfolio review
✓ raw material documentation checks
✓ zinc and aluminium concentration recalculations
✓ PIF and CPSR updates
✓ stock and transition deadline planning

Key dates include 1 January 2027 for placing non-compliant products on the EU market and 1 July 2028 for making them available on the market.

We have prepared a practical overview of the affected ingredients, deadlines and compliance actions for cosmetic companies.

If your products contain any of the affected ingredients, Annel can support ingredient compliance checks, PIF review and CPSR updates for the EU and UK markets.

04/05/2026

When does an “antibacterial” claim stop being cosmetic?

Claims such as antibacterial, antiseptic and antiviral can change how a product is classified. In practice, one phrase on pack or in an online listing may move a product from cosmetic into biocide or even medicine.

In our new article, we explain:

why the UK and EU do not approach this risk in the same way
why “kills 99.9% bacteria” can be treated very differently across markets
why Amazon and cross-border e-commerce create extra classification risk
why antiviral claims are especially sensitive

If your product sits close to the cosmetic-biocide borderline, this is not just a wording issue. It is a regulatory and commercial one.

Read the article here:

Learn when antibacterial, antiseptic and antiviral claims can move a product from cosmetic into biocide or medicine across the EU, UK and USA.

23/04/2026

UK REACH reform is moving forward, and for brands selling in Great Britain, this is about far more than delayed deadlines.

Yes, the registration timetable has moved. But the bigger question is whether your ingredients, suppliers and documentation will remain stable for the GB market in the years ahead.

For cosmetic brands, this can quickly turn into:
• reformulation pressure
• artwork and label review
• supplier uncertainty
• portfolio risk across UK and EU markets

Our new article explains what the UK REACH changes really mean, how ATRm fits in, and why earlier regulatory review matters.

Read the full article here:
https://annelltd.com/uk-reach-reform-2026/?utm_source=facebook&utm_medium=social&utm_campaign=blog_articles&utm_content=uk_reach_reform_2026_facebook

15/04/2026

A cosmetic product does not need to change formula to create regulatory risk.

Sometimes the claim is enough.

There is a major regulatory difference between:
“helps reduce the visible appearance of fine lines”
and
“stimulates collagen production.”

The formula may be identical.
The classification risk is not.

That is exactly why borderline review should happen before artwork approval, not after launch planning is already underway.

In our new article, we explain how the cosmetic-medicinal borderline is assessed across the EU, UK and USA, and why wording, presentation and intended use can change the regulatory position of a product.

Read here:
https://annelltd.com/cosmetic-medicinal-product-borderline/?utm_source=facebook&utm_medium=social&utm_campaign=borderline_article

02/04/2026

Children’s makeup ≠ harmless product category.

From a regulatory perspective, it is one of the highest-risk segments in cosmetics.

If a product is applied to the skin, it is not a toy - it is a cosmetic.
That means full compliance with EU Cosmetic Regulation.

What we see in practice:

incorrect classification
missing CPSR
ingredient risks

And the consequences:

marketplace removals
regulatory action
reputational damage

👉 Read more:
https://annelltd.com/children-makeup-compliance-eu-uk/?utm_source=facebook&utm_medium=social&utm_campaign=children_makeup_compliance&utm_content=post1

26/03/2026

Hexyl Salicylate and Methyl Salicylate are not the same compliance task.

Our new article explains why these ingredients should not be reviewed under one universal checklist.

The key differences include:
✔ different EU and GB timelines
✔ different child-exposure logic
✔ different transition windows
✔ different review workflows for regulatory teams

If your portfolio contains one or both of these ingredients, this is a practical compliance issue, not just a scientific detail.

Read more here:
https://annelltd.com/hexyl-vs-methyl-salicylate/?utm_source=facebook&utm_medium=organic&utm_campaign=blog_hexyl_vs_methyl_salicylate